Bristol Myers Squibb (BMY) announced that the European Medicines Agency (EMA) has validated its type II variation application for immunotherapy drug Opdivo (nivolumab), in combination with Yervoy (ipilimumab).The application seeks approval of Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma (HCC) who have not received any prior systemic therapy.The application is based on results from the late-stage CheckMate -9DW trial, ...

Defensive stocks are stealing the spotlight again following Fed Chair Jerome Powell’s recent comments.In his address at the Economic Club of Washington D.C., Powell talked about the precarious state of the economy. His remarks emphasized the stickiness in inflation, policy uncertainties, and large deficits amid full employment. Hence, given the breadth of variables impacting the economy, it seems like a tough road ahead for those expecting quick monetary easing. The Federal Reserve plans to approach policy ...

The market expects Bristol Myers Squibb (BMY) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be rel ...

The latest trading session saw Bristol Myers Squibb (BMY) ending at $42.39, denoting a -1.76% adjustment from its last day's close. This change lagged the S&P 500's 0.78% loss on the day. Elsewhere, the Dow saw a downswing of 1.29%, while the tech-heavy Nasdaq depreciated by 0.7%.Prior to today's trading, shares of the biopharmaceutical company had gained 5.73% over the past month. This has outpaced the Medical sector's gain of 2.23% and the S&P 500's gain of 2.14% in that time.Market participants will be c ...

hapabapa When looking at different pharmaceutical stocks, we see several companies rather struggling in the last few years. Of course, not every company and stock is struggling - Novo Nordisk (NVO) and Eli Lilly (LLY) for example, continue to rush from all-time high to all-time high. But stocks like Pfizer (PFE) and Bristol-Myers Squibb (NYSE:BMY) are declining lower and lower in the last few quarters. And the S&P Pharmaceutical ETF barely moved in the last five years while the S&P 500 (SPY) rushed from all ...

Andre Banyai/iStock via Getty Images BMY's Investment Thesis Is Closely Tied To The Potential Reversal In Its Patent Cliff & Rich Dividend Yields We previously covered Bristol-Myers Squibb Company (NYSE:BMY) in April 2024, discussing why we had finally rated the stock as a Buy as it offered a relatively rich forward dividend yield of 5.02% at the time of writing with the Seeking Alpha Quant still grading its payout safety as B-. Combined with its promising profitability metrics and its overly discounted ...

According to NextEarningsDate.com, the Bristol-Myers Squibb next earnings date is projected to be 7/26 before market open, with earnings estimates of $1.53/share on $10.56 Billion of revenue.Looking back, the recent Bristol-Myers Squibb earnings history looks like this:BMYtickertechThe company has the following long-term earnings per share chart:BMYtickertechAnd with impressive revenue growth:BMYtickertechBut earnings reports can often uniquely bring abrupt volatility to a stock, in either direction, as inv ...

Makhbubakhon IsmatovaStock market investing is sometimes referred to as a giant casino, in which day to day price movements are hard to predict, due to the multitude of variables and external events that can influence prices. Unlike the casino, however, the market is not a zero-sum game, unless if you’re trading options because so long as you’re willing to play the long game, your win doesn’t have to equate to someone else’s loss, and vice versa. That’s why I’d much rather put capital to work and risk i ...

These stocks all yield more than 3%.Dividend stocks haven't been taking off these days, and that's in part due to high interest rates. When investors can get healthy returns from low-risk, interest-paying assets, the case for buying dividend stocks is naturally less appealing. But the good news for long-term investors is that this means stock prices for some solid dividend stocks are low, and there are some enticing deals available right now.Bristol Myers Squibb (BMY -0.71%), Cisco Systems (CSCO 1.33%), and ...

文章核心观点 - 辉瑞和百时美施贵宝虽过去几年表现落后于市场，但两只股票值得本月买入，适合投资期限超五年的投资者 [1] 辉瑞 - 市场对辉瑞新冠疫苗市场初期成功反应过度，2020年末和2021年股价涨幅过大过快，如今新冠相关销售暴跌，市场或再次反应过度致股价持续下跌，但公司前景在改善 [2] - 过去几年辉瑞对产品线和研发管线进行重大改造，新获批速度超同规模同行，通过一系列收购拥有丰富多样临床资产组合 [2] - 辉瑞以430亿美元收购癌症专科公司Seagem，计划到2030年在肿瘤领域拥有8款重磅药物，目前有5款但部分销售额下降，计划到本十年末研发和推广超30亿美元癌症药物 [3] - 辉瑞与BioNTech合作开发更多mRNA产品，包括处于后期研究的潜在新冠/流感组合疫苗，还与Flagship Pioneering合作，首先瞄准快速增长的减肥领域 [3] - 辉瑞过去几年举措得益于新冠市场成功，鉴于研发管线深度，公司将持续取得临床和监管胜利，虽短期不稳定，但能扭转局面为有耐心投资者带来丰厚回报，当前价位适合长期投资者 [4] 百时美施贵宝 - 近几个季度百时美施贵宝营收增长缓慢，畅销药阿哌沙班和欧狄沃在本十年末面临专利到期，股价落后于市场 [5] - 百时美施贵宝仍是创新型公司，尤其在肿瘤领域，2019年以来获得多项新批准药物，影响力逐渐提升 [5] - 新药Reblozyl和Opdualag销售表现良好，2023年Reblozyl营收10亿美元，同比增长41%，Opdualag销售额6.27亿美元，同比增长近149% [6] - 新药有望获得重要适应症扩展，推动公司营收增长，研发管线将助力推出新的畅销药，虽本十年末专利到期营收会下降，但公司持续研发新药，股价下跌时适合买入 [7]